MIRM ▲ +8.7% - Mirum Pharmaceuticals, Inc.
$MIRM Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
12-OCT-2026 08:02 AM ET
Share this post
More filings for $MIRM
MIRM ▲ +5.3% - Mirum Pharmaceuticals, Inc.Oct 12, 2026MIRM ▲ +5.1% - Mirum Pharmaceuticals, Inc.Sep 28, 2026MIRM ▲ +2.2% - Mirum Pharmaceuticals, Inc.Sep 27, 2026MIRM - Mirum Pharmaceuticals, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026MIRM - Mirum Pharmaceuticals, Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026
View full $MIRM filing history →💬 Comments
Loading comments…
Leave a comment